Immunobiologicals are a reality in current clinical practice and have increasingly gained space in the inflammatory disease scenario, especially in dermatology, with approved drugs for psoriasis, atopic dermatitis, and hidradenitis suppurativa, in addition to many others undergoing study. It is important for dermatologists to have knowledge of the medications approved in Brazil, for the best management of dermatoses, in addition to the fact that they represent hope for improvement in patients with chronic diseases.
The interplay between metabolic health and autoimmune diseases such as psoriasis (PsO) and psoriatic arthritis (PsA) has garnered increasing attention. Obesity, a key feature of metabolic syndrome, exacerbates disease severity in these conditions, prompting the exploration of treatments addressing both the immune system and metabolism. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), primarily used for type 2 diabetes mellitus, have demonstrated benefits beyond glycemic control, including promoting weight loss, improving metabolic health, and potentially modulating immune responses. There is also a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist with similar and potentially superior capabilities; throughout this manuscript these will be collectively known as GLP-1RA. Recent studies also suggest that GLP-1RAs may help manage PsO and PsA in patients with obesity. These medications may offer dual benefits by reducing inflammation and addressing metabolic abnormalities like insulin resistance and hyperlipidemia. This article reports on a presentation given at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting underscoring the potential of GLP-1RAs as a therapeutic option, particularly for obese patients with PsO and PsA. Although promising, the evidence supporting GLP-1RAs for treating PsO and PsA remains limited, necessitating further clinical research to evaluate their safety and efficacy.
Young-GRAPPA (Y-GRAPPA) was introduced at the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting. Here we present the 1-year progress of Y-GRAPPA and future plans of this enthusiastic group of young clinicians and early career researchers interested in psoriasis and psoriatic arthritis.
The 1st GRAPPA International Meeting on Psoriasis and Psoriatic Arthritis – 1° Encontro Internacional do GRAPPA Sobre Psoríase e Artrite Psoriásica was held on August 18-19, 2023, in São Paulo, Brazil, and marked a turning point in the management of psoriasis (PsO) and psoriatic arthritis (PsA) in our country. This was an international collaboration, between Brazilian rheumatologists and dermatologists and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), aiming to promote medical knowledge and particularly the optimal care and management of Brazilian patients with psoriatic disease (PsD).
Artificial intelligence (AI) is increasingly gaining ground in dermatology, with studies reporting accuracy equal to or greater than dermatologists for the diagnosis of skin lesions from clinical and dermoscopic images.1 AI has been developed and improved constantly for dermatology, however, the focus has been much more on neoplastic diseases, due to their high prevalence and high morbidity. Describe the possible applications of AI in inflammatory dermatoses. Articles published between 2013 and 2023 in Medline and Lilacs were retrieved after applying the inclusion and exclusion criteria 19 articles were selected. From each selected article, the necessary information was extracted and with this data, the present review was written. The first studies on AI in dermatology focused on the diagnosis of neoplasms, especially melanoma, due to the ease of standardization of images, obtaining accuracy equivalent to that of a dermatologist in clinical and dermoscopic lesions. Actually, there are many studies on artificial intelligence in inflammatory dermatosis, such as psoriasis, helping to calculate the PASI, hidradenitis suppurativa, and atopic dematitis. The limitation of the study is that it is a literature review and because it is an innovative topic with a limited number of studies published in the literature. Considerable of what is published in the literature is in computer science journals, but it is possible to perceive that there is an important interest in the area and that artificial intelligence will advance to assist dermatologists.